# rheumatoid arthritis - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 4
- Task type: DISEASE-STATE
- Tissue / sample source: synovial tissue
- Comparison or endpoint: rheumatoid arthritis versus normal control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d868ce3efb219458b8d5ddb7b123eef3f2b718852ba0ede74f2a02e9181db293
- Response HTTP status: 200
- Prompt tokens: 4077
- Completion tokens: 22671
- Reasoning tokens: 
- Total tokens: 26748
- API requests reported: 
- Elapsed seconds: 218.4
- Final benchmark system: raw; file rank 3/5; original repeat 4; model vendor: DeepSeek

---
## Important scope note

The supplied table contains **only genes with negative log₂FC values**; there is no upregulated gene list and no hazard-ratio/prognostic information. Therefore, this interpretation is restricted to the **downregulated transcriptomic component in rheumatoid arthritis synovial tissue compared with normal control**. Inflammatory or upregulated programs cannot be inferred from this dataset alone, and no prognostic conclusions can be drawn.

---

## 1. Overall biological interpretation

The downregulated genes are not dominated by classic immune or inflammatory mediators. Instead, they converge on:

- **Cytoskeletal and cell-polarity machinery**: *SCRIB, APC2, ARVCF, INF2, CROCC, CROCC2, CROCCP2, DMPK, PPP1R12C, PLEKHH3, ACAP3, ARHGAP33*
- **Chromatin and transcriptional regulators**: *CBX7, PAGR1, HDGFL2, TNRC18, SIX5, FLYWCH1, ZNF316, ZNF219, ZNF444, ZNF580*
- **RNA metabolism and noncoding RNA landscape**: *CNOT12, SCAF1, GIGYF1, TELO2, NOL3, RNA5-8SN2/3/4, SNORD167, SCARNA17, multiple MIR genes, antisense lncRNAs*
- **An unexpected set of mucin/junction/surface markers**: *MUC5B, MUC6, MUC12, CDHR5, GJC2*

The most coherent interpretation is that the downregulated component of the RA synovial transcriptome reflects **loss or dilution of resident synovial structural/homeostatic programs**, potentially including altered lining-cell phenotype and reduced expression of cytoskeletal, polarity, and RNA-regulatory machinery. This could reflect true transcriptional downregulation within resident synoviocytes, or a relative decrease in those cell populations due to immune-cell infiltration and fibroblast activation. Because no upregulated genes were provided, this interpretation is necessarily one-sided and should not be read as a complete model of RA synovial biology.

---

## 2. Core biological programs

### Program 1: Cytoskeletal organization, centrosome/cilia, and cell polarity

- **Direction**: Downregulated in RA
- **Supporting genes**: *SCRIB, APC2, ARVCF, INF2, CROCC, CROCC2, CROCCP2, DMPK, PPP1R12C, PLEKHH3, ACAP3, ARHGAP33*
- **Pathway anchors**:
  - GO: microtubule cytoskeleton organization
  - GO: establishment or maintenance of cell polarity
  - KEGG: regulation of actin cytoskeleton; tight junction
- **Interpretation**: These genes collectively encode actin/microtubule regulators, centrosomal rootlet components, Rho-family signaling modulators, and polarity scaffolds. Their co-downregulation suggests reduced expression of cytoskeletal organising machinery in RA synovial tissue.
- **Strength and limitations**: Statistically very strong, with multiple independent genes. However, the program is broad and could be influenced by tissue composition; for example, loss of normal lining fibroblasts or vascular/stromal cells would produce a similar pattern.

### Program 2: Chromatin and transcriptional regulatory machinery

- **Direction**: Downregulated in RA
- **Supporting genes**: *CBX7, PAGR1, HDGFL2, TNRC18, ZNF316, ZNF219, ZNF444, ZNF580, SIX5, FLYWCH1*
- **Pathway anchors**:
  - GO: chromatin organization
  - GO: histone modification
  - Reactome: chromatin modifying enzymes
- **Interpretation**: Multiple genes involved in Polycomb repression, histone-methylation cofactor activity, zinc-finger DNA binding, and developmental transcription are downregulated. This could indicate an altered epigenetic landscape in RA synoviocytes, potentially affecting cell identity and activation thresholds.
- **Strength and limitations**: Supported by many genes, but the category is broad and includes several poorly characterised zinc-finger proteins. Downregulation of transcription-related genes may also reflect global transcriptional shutdown or cell-composition shifts rather than a specific RA mechanism.

### Program 3: RNA metabolism and noncoding RNA landscape

- **Direction**: Downregulated in RA
- **Supporting genes**: *CNOT12, SCAF1, GIGYF1, TELO2, NOL3, RNA5-8SN2/3/4, SNORD167, SCARNA17, MIR3183, MIR3615, MIR3154, MIR937, MIR4763, MIR647, MIR4492, MIR6821, MIR4730, MIR4665, MIR1301, PCGF3-AS1, CXXC5-AS1, TNK2-AS1, TBX2-AS1, DM1-AS*
- **Pathway anchors**:
  - GO: mRNA processing
  - GO: ncRNA processing
  - GO: rRNA processing
- **Interpretation**: There is a broad downregulation of both RNA-processing/decay factors and many noncoding RNA species, including microRNAs, small nucleolar RNAs, small Cajal body RNAs, ribosomal 5.8S RNA genes, and antisense lncRNAs. This pattern suggests altered post-transcriptional regulation or reduced ribosome biogenesis in RA synovial tissue.
- **Strength and limitations**: Numerically strong, but many noncoding loci are unannotated and difficult to interpret. rRNA and snoRNA signals in particular can be affected by RNA quality, library preparation, and ribosomal RNA depletion methods.

### Program 4: Mucin/glycocalyx and homeostatic lining/surface program

- **Direction**: Downregulated in RA
- **Supporting genes**: *MUC5B, MUC6, MUC12, CDHR5, GJC2*
- **Pathway anchors**:
  - Reactome: O-linked glycosylation of mucins
  - GO: cell-cell junction organization
- **Interpretation**: This is the most tentative program. It identifies co-downregulation of gel-forming and transmembrane mucins, a cadherin-related gene, and a gap-junction connexin. If confirmed in synovial lining cells, this could reflect loss of a homeostatic surface/junction phenotype. However, mucins are not canonical synovial genes, and this signal may reflect tissue contamination, sample heterogeneity, or non-synovial cell content in the comparator tissue.
- **Strength and limitations**: Statistically strong but biologically uncertain. This program should be treated as **insufficient evidence for a true synovial mucin program** until validated by protein localisation or single-cell transcriptomics.

---

## 3. Key genes and interaction modules

### 1. Cell polarity / cytoskeleton module
- **Genes**: *SCRIB, APC2, ARVCF, INF2, CROCC, CROCC2*
- **Statistical direction**: All downregulated; log₂FC approximately −2.76 to −4.99, FDR < 1e-37.
- **Role**: Core component of Program 1.
- **Proposed relationships**: Pathway co-membership and co-expression in this dataset. *CROCC* and *CROCC2* are sequence-related centrosomal/rootlet genes. *SCRIB*, *APC2*, and *ARVCF* are linked through cell-polarity/adherens-junction biology, but direct physical interaction among all members is not established by these data.

### 2. Mucin / junction module
- **Genes**: *MUC5B, MUC6, MUC12, CDHR5, GJC2*
- **Statistical direction**: All downregulated.
- **Role**: Candidate Program 4; potential homeostatic surface phenotype.
- **Proposed relationships**: Co-expression and pathway co-membership in mucin-type O-glycosylation/junction biology. *MUC5B* and *MUC6* are gel-forming mucins, while *MUC12* is a transmembrane mucin; *CDHR5* is a cadherin-related protein; *GJC2* is a connexin. No direct physical interaction is inferred.

### 3. Chromatin / epigenetic module
- **Genes**: *CBX7, PAGR1, HDGFL2, TNRC18, ZNF316, ZNF219, ZNF444, ZNF580*
- **Statistical direction**: All downregulated.
- **Role**: Core component of Program 2.
- **Proposed relationships**: Co-expression and regulatory/chromatin pathway co-membership. *CBX7* is a PRC1 component; *PAGR1* associates with the PAXIP1/PTIP histone-methylation complex. These individual complex associations are known, but the co-downregulation across the full gene set does not itself demonstrate direct physical interaction.

### 4. RNA metabolism module
- **Genes**: *CNOT12, SCAF1, GIGYF1, TELO2*
- **Statistical direction**: All downregulated.
- **Role**: Core component of Program 3.
- **Proposed relationships**: Pathway co-membership in mRNA fate control: deadenylation, splicing/coupling, translational repression, and PIKK kinase assembly. Direct physical interactions among these four are not established by the current data.

### 5. Noncoding RNA module
- **Genes**: *MIR3183, MIR3615, MIR3154, MIR937, MIR4763, MIR647, MIR4492, MIR6821, MIR4730, MIR4665, MIR1301, SNORD167, SCARNA17, RNA5-8SN2/3/4, PCGF3-AS1, CXXC5-AS1, TNK2-AS1, TBX2-AS1*
- **Statistical direction**: All downregulated.
- **Role**: Supporting Program 3; altered noncoding RNA landscape.
- **Proposed relationships**: Co-expression and likely regulatory relationships. Some antisense lncRNAs, such as *TBX2-AS1* and *TNK2-AS1*, may act in cis on nearby genes, but direct physical/regulatory evidence is not provided here.

### 6. DM1 locus module
- **Genes**: *DMPK, SIX5, DM1-AS*
- **Statistical direction**: All downregulated.
- **Role**: *DMPK* relates to cytoskeletal kinase function; *SIX5* is a transcription factor; *DM1-AS* is a noncoding antisense transcript.
- **Proposed relationships**: Genomic co-localisation and potential cis-regulatory interaction. *DM1-AS* is antisense to *DMPK*, suggesting a regulatory interaction, but direct physical interaction in RA synovium is unknown. This locus is classically associated with myotonic dystrophy, not RA, so its disease relevance here is uncertain.

### 7. *SH2B1* — single-gene candidate
- **Statistical direction**: Downregulated; log₂FC −2.28.
- **Role**: Adaptor protein that can modulate JAK/STAT-family signalling.
- **Proposed relationships**: No direct interaction with the other listed genes is inferred from this dataset. It is included because JAK/STAT signalling is clinically relevant in RA, but this is a single-gene signal and remains exploratory.

### 8. *ADAMTS7* — single-gene candidate
- **Statistical direction**: Downregulated.
- **Role**: Secreted metalloproteinase involved in matrix biology.
- **Proposed relationships**: None inferred with other listed genes. Its downregulation in synovial tissue is interesting given joint matrix remodeling in RA, but the current dataset cannot establish whether this reflects synovial expression or contribution from adjacent tissue types.

---

## 4. Validation priorities

### 1. Confounding / tissue-composition check
- **Classification**: Confounding or composition check
- **Why priority**: Many downregulated genes, especially mucins and non-synovial markers, could reflect differences in tissue composition rather than disease-specific transcriptional change.
- **Current evidence**: All genes in the supplied table are downregulated; some are atypical for synovium.
- **External evidence**: RA synovium is characterised by lining hyperplasia, immune infiltration, and altered fibroblast subsets; normal synovium contains more adipose/stromal tissue. This supports the plausibility of composition-driven signals.
- **Next step**: Perform single-cell RNA-seq or spatial transcriptomics on RA versus normal synovium; use bulk deconvolution approaches; validate protein localisation by multiplex immunohistochemistry.
- **Conclusion status**: Current biological conclusions should be considered **exploratory** until composition is formally addressed.

### 2. Mechanistic hypothesis: cytoskeleton/polarity in fibroblast-like synoviocyte behaviour
- **Classification**: Mechanistic hypothesis
- **Why priority**: The cell-polarity/cytoskeletal module is biologically coherent and could be relevant to the invasive phenotype of RA fibroblast-like synoviocytes.
- **Current evidence**: Robust co-downregulation of *SCRIB, APC2, ARVCF, INF2, CROCC* in RA synovium.
- **External evidence**: These genes control cell migration, polarity, and cytoskeletal dynamics in other cell types; RA FLS are known to be invasive. Direct RA-specific evidence for this module is limited.
- **Next step**: CRISPR-mediated knockdown of *SCRIB* or *INF2* in RA FLS; assess migration, invasion, focal adhesion, and polarity.
- **Conclusion status**: **Exploratory hypothesis**.

### 3. Interaction/network hypothesis: noncoding RNA and RNA-metabolism node
- **Classification**: Interaction / network hypothesis
- **Why priority**: The simultaneous downregulation of RNA-processing factors, miRNAs, snoRNAs, and antisense lncRNAs suggests a coordinated post-transcriptional regulatory module.
- **Current evidence**: Multiple independent RNA-related genes and noncoding RNAs are downregulated.
- **External evidence**: Antisense lncRNAs can regulate nearby genes; *GIGYF1* is involved in translational repression; *CNOT12* functions in mRNA deadenylation. However, the specific network proposed here is not established.
- **Next step**: CRISPRi perturbation of selected antisense lncRNAs; RNA stability assays; RNA–DNA interaction assays for cis-regulatory candidates.
- **Conclusion status**: **Exploratory hypothesis**.

### 4. Biomarker: mucin/junction/homeostatic surface module
- **Classification**: Biomarker
- **Why priority**: If the mucin/junction downregulation reflects loss of a normal synovial lining phenotype, it could be a tissue biomarker for lining de-differentiation.
- **Current evidence**: Co-downregulation of *MUC5B, MUC6, MUC12, CDHR5, GJC2* with high statistical significance.
- **External evidence**: Mucins are not established markers of synovial lining; this conflicts with known synovial tissue biology. The signal may be a composition artifact.
- **Next step**: Independent cohort validation using microdissected synovial lining/sublining, qRT-PCR, and protein localisation.
- **Conclusion status**: **Insufficient evidence** as a synovial biomarker; **exploratory hypothesis** at best.

### 5. Therapeutic target: CBX7 / chromatin module
- **Classification**: Therapeutic target
- **Why priority**: Chromatin regulators can reprogram cell state, and *CBX7* is a component of PRC1.
- **Current evidence**: *CBX7* and multiple chromatin regulators are downregulated in RA synovium.
- **External evidence**: CBX7/PRC1 have context-dependent roles in proliferation, senescence, and inflammation, but there is no established RA-specific therapeutic evidence. The existence of drugs targeting epigenetic regulators does not constitute evidence of efficacy in RA.
- **Next step**: Inducible overexpression or silencing of *CBX7* in RA FLS; assess inflammatory cytokine output, proliferation, and transcriptome changes; follow with fibroblast-specific in vivo studies.
- **Conclusion status**: **Exploratory hypothesis**; not an established therapeutic target.

---

## 5. Evidence grounding

- **Direct evidence from input dataset**: Transcript-level downregulation with very high statistical significance. No protein, functional, or clinical outcome data are directly provided.
- **Pathway/ontology evidence**: Gene annotations support grouping into cytoskeleton/polarity, chromatin/transcription, RNA metabolism, and mucin/junction programs.
- **Protein interaction/regulatory evidence**: Some known interactions exist within specific complexes, e.g., CBX7 in PRC1 and PAGR1 with PAXIP1. However, co-downregulation in this dataset is not evidence of direct physical interaction.
- **Disease-association evidence**: RA relevance of FLS invasion and JAK/STAT signalling provides indirect context, but most specific genes in this list are not established RA genes.
- **Expression/tissue-specific evidence**: Several genes are atypical for synovium, especially mucins and certain neuronal/retinal markers; this raises composition concerns.
- **Genetic/clinical evidence**: *DMPK/SIX5/DM1-AS* are genetically linked to myotonic dystrophy, not RA. No RA genetic or clinical validation is provided here.
- **Drug/therapeutic evidence**: None exists in the current dataset. The presence of a drug targeting a related pathway should not be interpreted as evidence of therapeutic relevance to RA.

---

## 6. Limitations and alternative explanations

### 1. Only downregulated genes were supplied
The dataset contains no upregulated genes and no hazard ratios. This prevents evaluation of the complete disease-state transcriptome and makes it impossible to determine whether these downregulated patterns occur alongside expected inflammatory activation. The absence of inflammatory genes in this table should not be interpreted as their absence in RA.

### 2. Tissue and cell-composition differences
RA synovium differs from normal synovium in cell composition: there is immune-cell infiltration, lining hyperplasia, and altered fibroblast subsets. Many of the observed downregulated genes may be expressed by normal stromal/adipose/vascular/possibly epithelial-contaminating cells and may appear “downregulated” only because those cells are relatively depleted in inflamed RA tissue.

### 3. Treatment exposure and clinical heterogeneity
RA patients are often treated with DMARDs, biologics, or corticosteroids, whereas normal controls are not. Drug effects could suppress many structural or metabolic genes. Disease duration, joint site, age, and sex were not provided, and all of these can influence synovial gene expression.

### 4. Technical and annotation limitations
The table includes many LOC genes, pseudogenes, snoRNAs, rRNA genes, and mitochondrial gene *ND1*. These are sensitive to RNA quality, library preparation, rRNA depletion, and annotation accuracy. Extreme p-values can also be inflated by large sample sizes, pseudoreplication, or overdispersed models if not properly controlled. These issues cannot be excluded without metadata and QC details.

### 5. Broad, nonspecific pathway signals and association-versus-causation
Cytoskeletal, chromatin, and RNA-metabolism programs are generic cellular processes. Their downregulation is not necessarily RA-specific and could be a consequence of cell-state changes rather than a driver. This is an associative transcriptomic signal, not causal evidence.

---

## Summary

The downregulated transcriptomic signature in RA synovium is robust and points toward loss of cytoskeletal/polarity, chromatin-regulatory, RNA-metabolic, and possible surface/homeostatic programs. The most important unresolved question is whether these changes are intrinsic to resident synoviocytes or reflect altered tissue composition. At present, the findings should be treated as a **well-powered descriptive signature with exploratory mechanistic and translational hypotheses**, not as established causal disease biology.
